Aytu biopharma announces closing of $4.0 million public offering priced at-the-market

Abhinav jain of nantahala capital management, llc joins the company's board of directors upon closing potential for additional $7 million in event of exercise of common warrants in full extends interest only period on avenue capital term loan through january 2025 maturity date englewood, co / accesswire / june 13, 2023 / aytu biopharma, inc. (nasdaq:aytu), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its equity offering co-led by nantahala capital management and stonepine capital management with participation by armistice capital of (i) 1,743,695 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 430,217 shares of its common stock ("pre-funded warrants"), and (ii) accompanying tranche a and tranche b warrants (the "common warrants") to purchase 4,347,824 shares of its common stock, priced at-the-market under the rules of the nasdaq capital market (the "offering"). gross proceeds, before deducting placement agent fees and other offering expenses, were approximately $4.0 million.
AYTU Ratings Summary
AYTU Quant Ranking